Implications for the use of topoisomerase I inhibitors in treatment of patients with systemic sclerosis.
Rudnicka
L
L
Department of Dermatology, Warsaw Medical School, Poland.
Czuwara
J
J
Barusińska
A
A
Nowicka
U
U
Makieła
B
B
Jabłonska
S
S
D002166:Camptothecin / Q000627:therapeutic use*; D003094:Collagen / Q000096:biosynthesis; D004264:DNA Topoisomerases, Type I / Q000096:biosynthesis; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000201:enzymology; D012867:Skin / Q000187:drug effects / Q000201:enzymology; D059004:Topoisomerase I Inhibitors
D004791:Enzyme Inhibitors; D007166:Immunosuppressive Agents; D059004:Topoisomerase I Inhibitors; D003094:Collagen; D004264:DNA Topoisomerases, Type I; D002166:Camptothecin